Corvus Starts Phase 1 for Renal Cell Cancer Treatment

 Corvus Pharmaceuticals, Inc, (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the initiation of a Phase 1b/2 clinical trial evaluating ciforadenant as a potential first line therapy for metastatic renal cell cancer (RCC) in combination with ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1). The Phase 1b/2 study is being conducted by the Kidney Cancer Research Consortium (KCRC) and is led by The University of Texas MD Anderson Cancer Center, one of seven partner institutions that make up the KCRC. The study is expected to enroll up to 60 patients at KCRC partner institutions.

https://www.biospace.com/article/releases/corvus-pharmaceuticals-announces-initiation-of-phase-1b-2-clinical-trial-of-ciforadenant-as-potential-first-line-treatment-for-patients-with-renal-cell-cancer/